Journal of Clinical Densitometry
Volume 9, Issue 4 , Pages 431-437 , October 2006

Effects of Alendronate on Bone Mineral Density in Men with Prostate Cancer Treated with Androgen Deprivation Therapy

  • Jan M. Bruder

      Affiliations

    • Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX
    • Corresponding Author InformationAddress correspondence to: Jan Bruder, Division of Endocrinology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229.
    • ,
  • J.Z. Ma

      Affiliations

    • Department of Psychiatry and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, TX
    • ,
  • N. Wing

      Affiliations

    • Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX
    • ,
  • J. Basler

      Affiliations

    • Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX
    • ,
  • D. Katselnik

      Affiliations

    • Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX

Received 9 June 2006 ,Revised 17 July 2006 ,Accepted 19 July 2006.

References 

  1. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–164
  2. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86:2787–2791
  3. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urology. 2000;163:181–186
  4. Kiratli Bj, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57:127–132
  5. Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Gaerber GJ, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. J Urology. 1999;54:607–611
  6. Suzuki Y, Aikawa K, Oishi Y, et al. A clinical study of decreased bone density in the patients treated with long-term luteinizing hormone releasing hormone analogue (LHRH-a)—the risk of iatrogenic osteoporosis due to treatment of carcinoma of prostate. Nippon Hinyokika Gakkai Zasshi. 1998;12:961–966
  7. Smith MR, McGovern FJ, Zeitman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948–955
  8. Mittan D, Miller E, Basler J, Lee S, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87:3656–3661
  9. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of Zolendronic Acid to prevent bone loss in men receiving androgen deprivation therapy for non metastatic prostate cancer. J Urol. 2003;169:2008–2012
  10. Diamond TH, Winters J, Smith A, De Souza P, Kersley JH, Lynch WJ, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer. 2001;92(6):1444–1450
  11. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):6410–6417
  12. Orwoll E, Ettinger M, Stuart W, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604–610
  13. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab. 2001;86(11):5252–5255
  14. The WHO Study Group . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization; 1994;
  15. Faulkner KG, Orwoll E. Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom. 2002;5:87–93
  16. Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the International Society for Clinical Densitometry. J Clin Densitom. 2004;7:17–26
  17. Looker AC, Orwoll ES, Johnston CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12(11):1761–1768
  18. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist–induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:3841–3846
  19. Bruder JM, Basler J, Welch MD. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen deprivation therapy. Urology. 2006;67:152–155
  20. Seeman E. The growth and age-related origins of bone fragility in men. Calcif Tissue Int. 2004;75:100–109
  21. McClung MR, Wasnich RD, Hosking DJ, et al. Prevention of postmenopausal bone loss—six year results from the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 2004;89(10):4879–4885
  22. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87(10):4528–4535
  23. Melton LJ, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res. 1998;13:1915–1923
  24. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med. 1996;101:488–501
  25. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. [see comments] Lancet. 1996;348:1535–1541
  26. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. [see comments] JAMA. 1998;280:2077–2082

PII: S1094-6950(06)00240-X

doi: 10.1016/j.jocd.2006.07.005

Journal of Clinical Densitometry
Volume 9, Issue 4 , Pages 431-437 , October 2006

Article Tools

* Image Usage & Resolution